Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3029% below fair value
$62.48+1.09 (+1.78%)
Close on Oct 30, 2026Market cap $127.63BP/E 13.9Yield 3.99%
Earnings
Bristol Myers Squibb's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 4, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$13.10B
+7.4% on a year earlier
non-GAAP EPS, Q3 FY2026
$1.35
$1.63 a year earlier
Latest guidance
Lowered
Oct 29, 2026 · 7 items
Quarterly results
Revenue and earnings per share from each of Bristol Myers Squibb's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 4, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 29, 2026before the open | $13.10B | +7.4% | $1.05 | $1.35 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 30, 2026before the open | $12.97B | +5.5% | $1.62 | $2.04 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 30, 2026before the open | $11.50B | +2.7% | $1.31 | $1.58 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 5, 2026before the open | $12.50B | +1.3% | $0.53 | $1.26 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 30, 2025before the open | $12.20B | +2.5% | $1.08 | $1.63 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 31, 2025before the open | $12.30B | +0.8% | $0.64 | $1.46 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 24, 2025before the open | $11.20B | -5.9% | $1.20 | $1.80 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 6, 2025before the open | $12.34B | +7.3% | $0.04 | $1.67 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 31, 2024before the open | $11.90B | +8.2% | $0.60 | $1.80 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 26, 2024before the open | $12.20B | +8.9% | $0.83 | $2.07 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 25, 2024before the open | $11.90B | +5.3% | -$5.89 | -$4.40 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 2, 2024before the open | $11.50B | +0.9% | $0.87 | $1.70 | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 26, 2023before the open | $11.00B | -1.8% | $0.93 | $2.00 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 27, 2023before the open | $11.20B | -5.9% | $0.99 | $1.75 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 27, 2023before the open | $11.30B | -5.7% | $1.07 | $2.05 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 2, 2023before the open | $11.40B | -5.0% | $0.95 | $1.82 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 26, 2022before the open | $11.20B | -3.4% | $0.75 | $1.99 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 27, 2022before the open | $11.90B | – | $0.66 | $1.93 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 18, 2022after the close | $11.99B | – | $1.07 | $1.84 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 4, 2022before the open | $12.00B | – | $1.07 | $1.83 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 27, 2021during market hours | $11.60B | – | $0.69 | $2.00 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 28, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 29, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 4, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Bristol Myers Squibb's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| 2026 WW Revenue Growth* | FY2026 | +10% – +15% | – | New | Apr 30, 2026 |
| Total Revenuesnon-GAAP | FY2026 | $49.75B – $50.25B | – | New | Oct 29, 2026 |
| Total Revenues (Reported & Ex-FX)non-GAAP | FY2026 | $49.00B – $50.00B | $46.00B – $47.50B | Raised | Jul 30, 2026 |
| Total Revenues (Reported & Ex-FX) | FY2026 | $46.00B – $47.50B | – | New | Apr 30, 2026 |
| Gross Margin %non-GAAP | FY2026 | 69% – 70% | – | New | Oct 29, 2026 |
| Gross Margin %non-GAAP | FY2026 | 69% – 70% | 69% – 70% | Reaffirmed | Jul 30, 2026 |
| Diluted EPSnon-GAAP | FY2026 | $6.75 – $7.00 | $6.05 – $6.35 | Raised | Jul 30, 2026 |
| Non-GAAP EPSnon-GAAP | FY2026 | $6.35 – $6.55 | – | New | Oct 29, 2026 |
| 2026 WW Revenue Growth | FY2026 | +20% – +25% | – | New | Oct 29, 2026 |
| 2026 WW Revenue Growth | FY2026 | +20% – +25% | – | New | Jul 30, 2026 |
| Effective tax ratenon-GAAP | FY2026 | 18% | – | New | Oct 29, 2026 |
| Effective tax ratenon-GAAP | FY2026 | 18% | – | New | Apr 30, 2026 |
| Operating Expensesnon-GAAP | FY2026 | $16.50B | – | New | Oct 29, 2026 |
| Operating Expensesnon-GAAP | FY2026 | $16.50B | $16.30B | Raised | Jul 30, 2026 |
| Other income/(expense)non-GAAP | FY2026 | -$650.00M | – | Lowered | Oct 29, 2026 |
| Other income/(expense)non-GAAP | FY2026 | -$700.00M | -$700.00M | Lowered | Jul 30, 2026 |
Guidance vs results
The last range Bristol Myers Squibb gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Non-GAAP EPS | $6.40 – $6.60 | $6.15Σ4Q | Below range |
| FY2025 | Revenue | $47.50B – $48.00B | $48.20BΣ4Q | Above range |
Guidance history
Every forecast Bristol Myers Squibb put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 29, 2026 | Non-GAAP EPS | FY2026 | $6.35 – $6.55 | New |
| Oct 29, 2026 | Gross Margin % | FY2026 | 69% – 70% | New |
| Oct 29, 2026 | 2026 WW Revenue Growth | FY2026 | +20% – +25% | New |
| Oct 29, 2026 | Other income/(expense) | FY2026 | -$650.00M | Lowered |
| Oct 29, 2026 | Operating Expenses | FY2026 | $16.50B | New |
| Oct 29, 2026 | Effective tax rate | FY2026 | 18% | New |
| Oct 29, 2026 | Total Revenues | FY2026 | $49.75B – $50.25B | New |
| Jul 30, 2026 | Diluted EPS | FY2026 | $6.75 – $7.00 | Raised |
| Jul 30, 2026 | Gross Margin % | FY2026 | 69% – 70% | Reaffirmed |
| Jul 30, 2026 | Operating Expenses | FY2026 | $16.50B | Raised |
| Jul 30, 2026 | Other income/(expense) | FY2026 | -$700.00M | Lowered |
| Jul 30, 2026 | 2026 WW Revenue Growth | FY2026 | +20% – +25% | New |
| Jul 30, 2026 | Total Revenues (Reported & Ex-FX) | FY2026 | $49.00B – $50.00B | Raised |
| Apr 30, 2026 | Diluted EPS | FY2026 | $6.05 – $6.35 | New |
| Apr 30, 2026 | Gross Margin % | FY2026 | 69% – 70% | New |
| Apr 30, 2026 | Operating Expenses | FY2026 | $16.30B | New |
| Apr 30, 2026 | Effective tax rate | FY2026 | 18% | New |
| Apr 30, 2026 | Other income/(expense) | FY2026 | -$700.00M | Lowered |
| Apr 30, 2026 | 2026 WW Revenue Growth* | FY2026 | +10% – +15% | New |
| Apr 30, 2026 | Total Revenues (Reported & Ex-FX) | FY2026 | $46.00B – $47.50B | New |
| Feb 5, 2026 | Total Revenues (Reported & Ex-FX) | FY2026 | $46.00B – $47.50B | New |
| Oct 30, 2025 | Non-GAAP EPS | FY2025 | $6.40 – $6.60 | Narrowed |
| Oct 30, 2025 | Gross Margin % | FY2025 | 72% | Reaffirmed |
| Oct 30, 2025 | Effective tax rate | FY2025 | 18% | Reaffirmed |
| Oct 30, 2025 | Operating Expenses | FY2025 | $16.50B | Raised |
| Oct 30, 2025 | other income and expense | FY2025 | $500.00M | Lowered |
| Oct 30, 2025 | non-GAAP revenue | FY2025 | $47.50B – $48.00B | Raised |
| Jul 31, 2025 | Non-GAAP EPS | FY2025 | $6.35 – $6.65 | New |
| Jul 31, 2025 | Gross Margin % | FY2025 | 72% | New |
| Jul 31, 2025 | Effective tax rate | FY2025 | 18% | New |
| Jul 31, 2025 | Operating Expenses | FY2025 | $16.50B | New |
| Jul 31, 2025 | other income/(expense) | FY2025 | $250.00M | Lowered |
| Jul 31, 2025 | Total Revenues (Reported & Ex-FX) | FY2025 | $46.50B – $47.50B | New |
| Apr 24, 2025 | Diluted EPS | FY2025 | $6.70 – $7.00 | Raised |
| Apr 24, 2025 | Gross Margin % | FY2025 | 72% | Reaffirmed |
| Apr 24, 2025 | Effective tax rate | FY2025 | 18% | Reaffirmed |
| Apr 24, 2025 | Operating Expenses | FY2025 | $16.20B | Raised |
| Apr 24, 2025 | Other income/(expense) | FY2025 | $100.00M | Lowered |
| Apr 24, 2025 | Total Revenues (Reported & Ex-FX) | FY2025 | $45.80B – $46.80B | Raised |
| Feb 6, 2025 | Diluted EPS | FY2025 | $6.55 – $6.85 | New |
| Feb 6, 2025 | Gross Margin % | FY2025 | 72% | New |
| Feb 6, 2025 | Operating Expenses | FY2025 | $16.00B | New |
| Feb 6, 2025 | Other Income/(Expense) | FY2025 | $30.00M | Lowered |
| Feb 6, 2025 | Tax Rate | FY2025 | 18% | New |
| Feb 6, 2025 | Total Revenues (Reported & Ex-F/X) | FY2025 | $45.50B | New |
| Oct 31, 2024 | Diluted EPS | FY2024 | $0.75 – $0.95 | Raised |
| Oct 31, 2024 | Gross Margin % | FY2024 | 74.5% – 75% | Raised |
| Oct 31, 2024 | Operating Expenses | FY2024 | +4% – +5% | New |
| Oct 31, 2024 | Total Revenues | FY2024 | +5% | New |
| Jul 26, 2024 | Diluted EPS | FY2024 | $0.60 – $0.90 | Raised |
| Jul 26, 2024 | Gross Margin % | FY2024 | 74% – 75% | Raised |
| Jul 26, 2024 | Effective tax rate | FY2024 | 66% | Lowered |
| Jul 26, 2024 | Other income/(expense) | FY2024 | -$50.00M | Raised |
| Apr 25, 2024 | Diluted EPS | FY2024 | $0.40 – $0.70 | Lowered |
| Apr 25, 2024 | Gross Margin % | FY2024 | 74% | Reaffirmed |
| Apr 25, 2024 | Effective tax rate | FY2024 | 69% | Raised |
| Apr 25, 2024 | Other income/(expense) | FY2024 | -$250.00M | Lowered |
| Feb 2, 2024 | non-GAAP EPS | FY2024 | $7.10 – $7.40 | New |
| Feb 2, 2024 | Non-GAAP Gross margin | FY2024 | 74% | New |
| Feb 2, 2024 | effective tax rate | FY2024 | 17.5% | New |
| Feb 2, 2024 | Other Income/(Expense) | FY2024 | $250.00M | New |
| Oct 26, 2023 | Non-GAAP diluted EPS | FY2023 | $7.50 – $7.65 | Raised |
| Oct 26, 2023 | GAAP diluted EPS | FY2023 | $3.68 – $3.83 | Lowered |
| Oct 26, 2023 | Gross margin % | FY2023 | 76% | Reaffirmed |
| Oct 26, 2023 | Gross margin % | FY2023 | 76% | Reaffirmed |
| Oct 26, 2023 | GAAP tax rate | FY2023 | 11% | Lowered |
| Oct 26, 2023 | Non-GAAP tax rate | FY2023 | 15.5% | Lowered |
| Oct 26, 2023 | total revenues for Revlimid | FY2023 | $6.00B | New |
| Jul 27, 2023 | Non-GAAP EPS | FY2023 | $7.35 – $7.65 | Lowered |
| Jul 27, 2023 | GAAP EPS | FY2023 | $3.72 – $4.02 | Lowered |
| Jul 27, 2023 | Gross Margin % | FY2023 | 76% | Lowered |
| Jul 27, 2023 | Gross Margin % | FY2023 | 76% | Lowered |
| Jul 27, 2023 | Tax Rate | FY2023 | 16% | Lowered |
| Jul 27, 2023 | Tax Rate | FY2023 | 17.5% | Raised |
| Jul 27, 2023 | Revenues from Revlimid | FY2023 | $5.50B | New |
| Apr 27, 2023 | Diluted EPS | FY2023 | $7.95 – $8.25 | Reaffirmed |
| Apr 27, 2023 | Diluted EPS | FY2023 | $4.10 – $4.40 | Raised |
| Apr 27, 2023 | Gross margin % | FY2023 | 77% | Reaffirmed |
| Apr 27, 2023 | Gross margin % | FY2023 | 77% | Reaffirmed |
| Apr 27, 2023 | Effective tax rate | FY2023 | 21% | Lowered |
| Apr 27, 2023 | Effective tax rate | FY2023 | 17% | Reaffirmed |
| Apr 27, 2023 | Total reported revenues | FY2023 | +2% | Reaffirmed |
| Apr 27, 2023 | Total reported revenues | FY2023 | +2% | Reaffirmed |
| Feb 2, 2023 | non-GAAP EPS | FY2023 | $7.95 – $8.25 | New |
| Feb 2, 2023 | GAAP EPS | FY2023 | $4.03 – $4.33 | New |
| Feb 2, 2023 | Gross margin | FY2023 | 77% | New |
| Feb 2, 2023 | Gross margin | FY2023 | 77% | New |
| Feb 2, 2023 | effective tax rate | FY2023 | 22% | New |
| Feb 2, 2023 | effective tax rate | FY2023 | 17% | New |
| Feb 2, 2023 | Total revenues | FY2023 | +2% | New |
| Feb 2, 2023 | Total revenues | FY2023 | +2% | New |
| Oct 26, 2022 | Diluted EPS | FY2022 | $7.44 – $7.74 | Reaffirmed |
| Oct 26, 2022 | Diluted EPS | FY2022 | $2.54 – $2.84 | Lowered |
| Oct 26, 2022 | Gross Margin % | FY2022 | 78% | Reaffirmed |
| Oct 26, 2022 | Gross Margin % | FY2022 | 79% | Reaffirmed |
| Oct 26, 2022 | Tax Rate | FY2022 | 24% | Raised |
| Oct 26, 2022 | Tax Rate | FY2022 | 16.5% | Reaffirmed |
| Oct 26, 2022 | Total Sales | FY2022 | $46.00B | Reaffirmed |
| Oct 26, 2022 | Total Sales | FY2022 | $46.00B | Reaffirmed |
| Jul 27, 2022 | Diluted EPS | FY2022 | $7.44 – $7.74 | Lowered |
| Jul 27, 2022 | Diluted EPS | FY2022 | $2.71 – $3.01 | Lowered |
| Jul 27, 2022 | Gross Margin % | FY2022 | 78% | Reaffirmed |
| Jul 27, 2022 | Gross Margin % | FY2022 | 79% | Raised |
| Jul 27, 2022 | Tax Rate | FY2022 | 23% | Lowered |
| Jul 27, 2022 | Tax Rate | FY2022 | 16.5% | Reaffirmed |
| Jul 27, 2022 | Total Net Sales | FY2022 | $46.00B | New |
| Jul 27, 2022 | Total Net Sales | FY2022 | $46.00B | New |
| Feb 4, 2022 | non-GAAP EPS | FY2022 | $7.65 – $7.95 | New |
| Feb 4, 2022 | GAAP EPS | FY2022 | $3.37 – $3.67 | New |
| Feb 4, 2022 | free cash flow generation | 2022-2024 | $45.00B – $50.00B | – |
| Feb 4, 2022 | Gross margin | FY2022 | 78% | New |
| Feb 4, 2022 | Gross margin | FY2022 | 78% | New |
| Feb 4, 2022 | effective tax rate | FY2022 | 24% | New |
| Feb 4, 2022 | effective tax rate | FY2022 | 16.5% | New |
| Feb 4, 2022 | Operating expenses | FY2022 | -10% | New |
| Feb 4, 2022 | Worldwide revenues | FY2022 | $47.00B | New |
| Oct 27, 2021 | non-GAAP EPS | FY2021 | $7.40 – $7.55 | New |
| Oct 27, 2021 | GAAP EPS | FY2021 | $2.68 – $2.83 | New |
| Oct 27, 2021 | Gross margin as a percentage of revenue | FY2021 | 79% | New |
| Oct 27, 2021 | Gross margin as a percentage of revenue | FY2021 | 80% | New |
| Oct 27, 2021 | effective tax rate | FY2021 | 26% | New |
| Oct 27, 2021 | effective tax rate | FY2021 | 16.5% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Bristol Myers Squibb filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- News
- News
- News
- Results
- Results
- Results